<DOC>
	<DOC>NCT03042741</DOC>
	<brief_summary>Atherosclerosis vaccine, V6, has been through two small-scale Phase II open label clinical trials. It has shown significant improvement in lipid profile in patients with overweight or obesity</brief_summary>
	<brief_title>Vaccine Against Atherosclerosis in Patients With Overweight Problems or Obesity</brief_title>
	<detailed_description>The proposed study will evaluate daily dose of one V6 pill administered for one month in placebo-controlled, randomized, double-blind phase 3 trial in men and women with baseline waist diameter over 90 and 80 cm respectively. The effect of V6 will be assessed by changes in lipid profile, i.e., LDL, HDL, TG and TC; anthropomorphic indices, i.e., circumference of waist, mid-arm, and hips; arterial blood pressure and fasting glucose levels at baseline versus post-treatment timepoint.</detailed_description>
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Baseline waist diameter over 90 and 80 cm for men and women, respectively Pregnant and lactating women Individuals with clinical symptoms or diseases who in opinion of study investigators are not eligible to participate</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>